It will establish new reference measurement procedures for established biomarkers in cerebrospinal fluid, found in the brain and spine, while also introducing procedures for potential new blood-based biomarkers.

This will support reliable, comparable measurements in current diagnostic tests and further the development of population-based screening through blood testing, which is urgently required to enable earlier diagnosis of Alzheimer’s disease.